MikroScore
Science-backed ingredient evidence
Moderate Evidence Safety: Likely safe Study dose: 100 mg/day

Akkermansia muciniphila

Also known as: Akkermansia, Akkermansia muciniphila, AKK

Summary Moderate Evidence

Akkermansia muciniphila is a gut bacterium linked to better metabolism, intestinal barrier function, and healthy aging in observational studies.

EU Health Claims: No approved claims

No EFSA health claims approved. Regulatory status as a supplement in the EU is still under clarification. Pasteurized Akkermansia is available as a novel food in some EU countries.

AI Summary

Quick verdict

Akkermansia muciniphila is a gut bacterium linked to better metabolism, intestinal barrier function, and healthy aging in observational studies.

What the evidence supports

Early human RCTs show metabolic benefits (insulin sensitivity, cholesterol). Observational studies associate high Akkermansia with healthy aging.

What is NOT supported

Long-term safety and rare adverse effects in humans remain insufficiently studied.

EU/EFSA status

Not approved. No EFSA health claims approved. Regulatory status as a supplement in the EU is still under clarif…

Safety

Likely safe

This AI summary is generated from the structured data on this page.

What is Akkermansia muciniphila?

Akkermansia muciniphila is a gram-negative bacterium that comprises 1–3% of a healthy adult’s gut microbiota. It uniquely colonizes the mucus layer lining the intestinal epithelium, where it literally feeds on mucins—the protein components of mucus itself. This ecological niche gives Akkermansia a dual role: it maintains the integrity of the intestinal mucus barrier while strengthening epithelial tight junctions, the cellular “seals” that prevent bacterial lipopolysaccharides (LPS) and other microbial components from leaking into the bloodstream—a phenomenon known as “leaky gut.”

Epidemiologically, this matters: people with high Akkermansia abundance tend to be leaner, metabolically healthier, and live longer. Centenarians (100+ years old) have unusually elevated Akkermansia levels compared to younger populations.

The research evidence

Positive findings

  • First human RCT (Depommier et al., 2019, n=40): Pasteurized Akkermansia administered daily for 12 weeks was associated with significant improvements in fasting insulin, HOMA-IR (insulin resistance index), LDL-cholesterol, and systemic inflammation markers in overweight adults.
  • Mechanistic specificity: The active component is the bacterial membrane protein Amuc_1100; even dead (pasteurized) cells retained efficacy in the human trial, suggesting immune and metabolic signaling rather than colonization per se.
  • Synergies with lifestyle: Observational data show Akkermansia abundance strongly predicts metabolic response to caloric restriction and exercise.
  • Barrier function: Multiple studies confirm Akkermansia’s role in strengthening intestinal barrier integrity, a key marker in metabolic and immunological health.

The caveats

  • Limited sample sizes: The landmark human RCT had only 40 participants, and follow-up studies remain few.
  • Short duration: Most human studies last 12 weeks; long-term outcomes (>1 year) are unknown.
  • Manufacturing variability: Akkermansia supplements vary widely in viability and storage stability. Product quality control is inconsistent.
  • No hard clinical endpoints yet: While metabolic biomarkers improved in the RCT, there are no data on weight loss, cardiovascular events, or lifespan in humans taking Akkermansia.

Mechanism: barrier integrity and immune tolerance

Akkermansia strengthens the intestinal barrier through several pathways:

  1. Mucus layer maintenance: By feeding on mucin, Akkermansia triggers increased mucin synthesis by goblet cells, thickening the mucus barrier.
  2. Tight junction support: Akkermansia-derived metabolites (especially short-chain fatty acids like propionate) enhance expression of claudins and occludin, proteins that seal epithelial gaps.
  3. Immune tolerance: Akkermansia and its membrane protein Amuc_1100 interact with immune cells, promoting IL-10 secretion and regulatory T cell (Treg) differentiation, reducing systemic inflammation.
  4. Metabolic signaling: Akkermansia-derived metabolites signal through GPCRs (e.g., GPR43, GPR109a) on intestinal and immune cells, favorably shifting metabolism toward insulin sensitivity and reduced obesity markers.

Dosage and formulation

  • Typical supplement: 10^9–10^10 CFU (colony-forming units) per dose if live; pasteurized forms at equivalent dry weight.
  • Dosing: 1–2 capsules daily with or without food; more data support with food or alongside prebiotic fiber (e.g., inulin, FOS), which Akkermansia can metabolize.
  • Timing: Consistent daily dosing recommended; effects typically appear over 6–12 weeks.

Safety and tolerability

Akkermansia is well-tolerated in human trials:

  • Mild GI symptoms (bloating, gas) in first 1–2 weeks, resolving spontaneously.
  • No serious adverse events reported in any published trial.
  • Caveat for immunocompromised individuals: While Akkermansia is a commensal bacterium, those with severe immunosuppression or active GI infections should consult a physician before use.

Regulatory and product quality considerations

  • EU status: Akkermansia supplements occupy a gray zone. Pasteurized forms are marketed as novel foods in some countries; live forms are often sold as supplements. Regulatory frameworks are still emerging.
  • EFSA: No approved health claims for Akkermansia.
  • Product quality: Live Akkermansia supplements may lose viability during storage. Pasteurized forms (used in the landmark RCT) may be more stable and reliable.

Bottom line

Akkermansia muciniphila is one of the most promising probiotic-like interventions in the metabolic health and healthy aging space. The first human RCT shows real metabolic benefits, and the mechanistic basis is strong. However, it remains early-stage: long-term efficacy, optimal dosing, and product reliability are still being established. If you’re interested in gut health and metabolic optimization, Akkermansia represents a data-backed choice—but manage expectations around lasting lifespan or disease prevention, which have not yet been demonstrated.

Key Studies

The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model

Plovier H et al. (2017)

Identification of Amuc_1100, an outer-membrane protein of Akkermansia, as an active component driving metabolic improvements in mice.

PubMed PMID 36085529

Supplementation with Akkermansia muciniphila in overweight and obese human volunteers

Depommier C et al. (2019)

First human RCT: Pasteurized Akkermansia was associated with improvements in insulin sensitivity, cholesterol, and body weight in overweight adults (n=40, 12 weeks).

PubMed PMID 31263284

Akkermansia muciniphila and improved metabolic health during caloric restriction

Dao MC et al. (2016)

Observational study: Higher baseline Akkermansia abundance correlated with better metabolic responses to caloric restriction.

PubMed PMID 26100928

Products with Akkermansia muciniphila

No reviewed products yet — we're working on it.

See all reviewed products →
Editorial notice: For most ingredients described here, no health claims are approved in the EU (Regulation (EC) 1924/2006). Evidence levels are editorial assessments of research quality — not health promises. This content is not a substitute for medical advice and does not constitute a recommendation to treat, alleviate, or prevent any disease.